Affidea Partners With Skin Analytics to Improve Access to Skin Cancer Assessment Across Europe Using AI Technology

As seen at Affidea.com Affidea, a leading pan-European provider of community-based polyclinics, advanced diagnostics, and multi-specialist care, including oncology, has entered a strategic partnership with Skin Analytics, a pioneering AI company in dermatology care. This collaboration supports Affidea’s long-term vision of leveraging digital innovations to improve patient outcomes as part of its integrated skin cancer care […]
NHS 10-Year Health Plan: For AI skin cancer pathways to be standard care by 2028, adoption needs to start now

While the NHS 10-Year Health Plan highlights that by 2028 AI skin cancer pathways will be standard of care, this is not the timeline for adoption. Rather this timeline aligns with the expected timing to mandated adoption across the NHS.
Skin Analytics invited to the Science Innovation and Technology Committee meeting

Neil Daly, CEO & founder of Skin Analytics, appeared before the UK Parliament’s Science, Innovation and Technology Committee as part of the ongoing inquiry titled: “Innovation Showcase: Reviewing the UK Science and Tech Landscape.”
AI skin cancer detection deployed into the Barking & Dagenham community with Together First CIC

Residents in Barking & Dagenham now have faster, more accurate access to skin cancer checks thanks to a new partnership between Skin Analytics and Together First CIC, the borough’s GP Federation.
Celebrating Double Wins at the HSJ Digital Awards

We are absolutely delighted to share that our collaborative work with NHS partners has been recognised with two prestigious awards at the HSJ Digital Awards!
AI technology to speed up diagnosis of skin cancer at Bridgewater Community Healthcare NHS Foundation Trust

Bridgewater Community Healthcare NHS Foundation Trust and Warrington and Halton Teaching Hospitals NHS Foundation Trust are using the latest in AI technology to provide patients with a swifter diagnosis of skin cancer.
5 Years of Bupa & Skin Analytics!

With 19,000 patients supported, we look back on 5 incredible years since Bupa launched a home-based service for skin cancer assessments with Skin Analytics.
Winners! The British Data Awards – AI Company of the Year

Skin Analytics took home the award for AI Company of the Year at the British Data Awards 2025.
NICE recommends DERM for early use within the NHS, while further evidence is gathered – Commentary from Neil Daly, Founder and CEO, Skin Analytics

On May 1st 2025, the National Institute for Health and Care Excellence (NICE) published its Early Value Assessment (EVA) of ‘Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathway’.
My skin health journey: through the decades

In this patient story, Giles shares his skin health journey through the decades and how he felt when a suspicious lump on his left temple led him to experience AI for skin cancer detection.
The American Academy of Dermatology (AAD) 2025

Clinical AI Lead at Skin Analytics, Dr Dilraj Kalsi presented how DERM is at least as good as dermatologists at safely ruling out melanoma at the American Academy of Dermatology
Skin Analytics raises £15 million funding to deliver AI skin cancer detection worldwide

Skin Analytics has secured £15 million in Series B funding led by Intrepid Growth Partners.
Future Medicine AI Hub Podcast: AI for dermatology

Dr Alice Plant, Consultant Dermatologist at University Hospitals Dorset NHS Foundation Trust, and Dr Dilraj Kalsi, Clinical AI Lead at Skin Analytics joined Future Medicine AI Hub to discuss how AI is proving to transform NHS dermatology services.
HSJ webinar | From Pilot to Autonomous AI: Transforming NHS Dermatology in an ICB

Register for this HSJ webinar to hear how primary and secondary care organisations across Suffolk and North East Essex ICB worked in partnership to deploy DERM.
Patient experience: Claire’s story

From sceptic to strong supporter: why I believe everyone should have access to AI skin cancer assessments.
Finalists for the HTN AI and Data Awards 2025

Following the implementation of DERM, Kingston and Richmond NHS Foundation Trust have been shortlisted for two HTN awards – Best use of AI for diagnosis, treatment and patient care & AI Solution of the Year.
New partnership with Bolton NHS Foundation Trust!

Bolton NHS Foundation Trust are the next Trust in Greater Manchester to deploy DERM into their urgent suspected skin cancer pathway.
Patient experience: Stevan’s story

In this personal account, Stevan shares his experience of AI for skin cancer detection following extensive exposure to the sun during time in the Service and mountaineering.
‘Global first as NHS hospital uses AI for instant skin cancer checks’ – The Times

The Times reports on Chelsea and Westminster Hospital NHS Foundation Trust deploying DERM autonomously, marking a new era for cancer care.
WINNERS: HSJ Partnership Awards 2025!

Skin Analytics and Chelsea and Westminster Hospital NHS Foundation Trust win the HSJ Partnership Award 2025 for Most Effective Contribution to Improving Cancer Outcomes.
DERM makes medical history as world’s first autonomous skin cancer detection system is approved for clinical decisions in Europe

The Class III CE marking under the European Medical Device Regulation (MDR) 2017/745 reflects the highest level of regulatory scrutiny and underlines DERM’s safety, accuracy and effectiveness in detecting cancer in patients without clinician review. al decisions on skin cancer without oversight marking a transformative era for global healthcare.
Patient experience: Jess’ Story

In this personal account, Jess shares her experience of the Skin Analytics pathway, what happened after she noticed a lump that had changed and how she felt about AI assessing her skin lesion.
WEBINAR: Autonomous AI in action – Tackling NHS backlogs and improving patient outcomes in dermatology

This webinar will showcase real NHS stories and expert insights into how AI as a Medical Device (AIaMD) is transforming dermatology waitlists, improving patient outcomes, and delivering measurable value across trusts.
Hear from NHS colleagues at Chelsea and Westminster Hospital NHS Foundation Trust (CWFT) about how they’re using DERM, the world’s first autonomous AIaMD for dermatology.
The Scrubbed In Show: AI-Powered Skin Cancer Detection for the NHS with Neil Daly, Skin Analytics CEO

In this week’s episode of The Scrubbed In Show podcast, our CEO Neil Daly shares his journey from consulting into building Skin Analytics.
Chelsea and Westminster Hospital NHS Foundation Trust pioneers the use of DERM, the world’s first autonomous Artificial Intelligence as a Medical Device for dermatology

Our longstanding NHS partner, Chelsea and Westminster Hospital NHS Foundation Trust, are now deploying DERM to identify and discharge patients with benign lesions, without validation from their dermatology team.
Finalists for the HSJ Partnership Awards 2025!

We’re delighted to be finalists for FIVE 2025 HSJ Partnership Awards alongside our NHS partners.
Service expansion! West Middlesex University Hospital launch a Skin Analytics pathway

West Middlesex University Hospital, part of Chelsea and Westminster Hospital NHS Foundation Trust, are set to deliver a post-referral service for suspected skin cancer using AI Teledermatology.
NHS Providers Conference 2024

Session recording now available to watch! At this year’s NHS Providers Conference, NHS University Hospitals of Liverpool Group shared value seen, learnings and future plans following the implementation of DERM.
HSJ Awards 2024

Last night we joined our partners, NHS Suffolk and North East Essex Integrated Care Board and Chelsea and Westminster Hospital NHS Foundation Trust to celebrate their nominations at the HSJ Awards 2024.
Heywood, Middleton & Rochdale (HMR) Integrated Care Partnership launches a pre-referral service for suspected skin cancer with Skin Analytics

Another NHS partnership! But this time with HMR in primary care! HMR will leverage AI-driven teledermatology to discharge patients with benign lesions earlier in the pathway before they reach secondary care. This will ultimately look to increase the conversion rate of patients with skin cancer into the Northern Care Alliance – where HMR refers into. […]